NCT02785250 2021-06-18Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian CancerImmunoVaccine Technologies, Inc. (IMV Inc.)Phase 1/2 Unknown85 enrolled
NCT01982487 2013-12-18Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in RemissionRoswell Park Cancer InstitutePhase 1/2 Withdrawn